secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001714899-25-000067
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali reports FY2024 net loss $422.8M; BLA for MPS II drug planned early 2025
------------------------------------------------------------------------------

- Net loss $114.8M Q4 and $422.8M FY2024, vs $119.5M and $145.2M in prior year.
- No collaboration revenue in 2024; FY2023 had $330.5M from Biogen, Sanofi, Takeda.
- New ATM equity facility up to $400M; prior ATM terminated; Goldman & Leerink agents.
- DNL343 (ALS) missed primary endpoint in HEALEY trial; further analyses expected H2 2025.
- 2025 cash opex guided +10-15% vs 2024; cash balance $1.19 billion as of Dec 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/0001714899-25-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/dnli-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer